Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma - PubMed (original) (raw)
Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma
Bradley H Edwards et al. J Virol. 2002 Mar.
Abstract
The importance of CD8+ T-cell responses in the control of human immunodeficiency virus type 1 (HIV-1) infection has been demonstrated, yet few studies have been able to correlate these responses with markers of HIV-1 disease progression. This study measured cell-mediated immune responses using peripheral blood mononuclear cells (PBMC) obtained from 27 patients with chronic HIV-1 infection, the majority of whom were off antiretroviral therapy. The ELISPOT assay was used to detect gamma interferon-secreting PBMC after stimulation with overlapping HIV-1 peptides spanning the Gag, Pol, Env, and Nef proteins in addition to the baculovirus-derived p24 and gp160 proteins. All volunteers had responses to at least one HIV-1-specific peptide. All but one of the subjects (96%) responded to the Gag peptide pool, and 86% responded to the Pol and/or Nef peptide pools. The magnitude and the breadth of T-cell responses directed to either the Gag or p24 peptide pools correlated inversely with viral load in plasma (r = -0.60, P < 0.001 and r = -0.52, P < 0.005, respectively) and directly with absolute CD4+ T-cell counts (r = 0.54, P < 0.01 and r = 0.39, P < 0.05, respectively) using the Spearman rank correlation test. Responses to the Pol and integrase peptide pools also correlated with absolute CD4+ T-cell counts (r = 0.45, P < 0.05 and r = 0.49, P < 0.01, respectively). No correlation with markers of disease progression was seen with specific T-cell responses directed toward the Env or Nef peptides. These data serve as strong evidence that major histocompatibility complex class I presentation of Gag peptides is an essential feature for any HIV-1 vaccine designed to elicit optimal CD8+ T-cell responses.
Figures
FIG. 1.
HIV-1-specific immune responses as measured by the IFN-γ ELISPOT assay. (A) Responses to Gag, Pol, Env, and Nef by measuring IFN-γ secretion using PBMC stimulated with overlapping 20-mer peptide pools are represented for each individual subject. (B) HIV-1-specific responses using the 20-mer peptides that correspond to the listed proteins are demonstrated for each subject. The black bar represents the median response among the cohort for each of the protein responses. The AA adjusted score is defined as the magnitude of responses (median SFU/106 PBMC) divided by the number of AA in the respective protein sequences. The 20-mer peptide pools exactly represent the Gag, Pol, Env, and Nef proteins. The 20-mer peptide pools represent the smaller proteins as follows. Gag: matrix protein p17 (AA 1 to 110), capsid protein p24 (AA 140 to 361), nucleocapsid protein NC (AA 399 to 500); Pol: protease Pr (AA 57 to 155), reverse transcriptase RT (AA 155 to 593), RNase H (AA 601 to 710), and integrase IN (AA 711 to 1003); Env: surface protein gp120 (AA 1 to 431) and transmembrane protein gp41 (AA 513 to 856). ∗, FOJA3818 had measurements performed at two separate time points.
FIG. 2.
HIV-1-specific immune responses correlate with vRNA and absolute CD4+ T-cell counts. HIV-1-specific immune responses as measured by the 20-mer IFN-γ ELISPOT assay were compared with either vRNA (A) or absolute CD4+ T-cell counts (B) using linear regression analysis. The P values are shown for the slope of each data set.
FIG. 3.
IFN-γ secretion of PBMC stimulated with Gag peptides is due primarily to CD8+ T cells. The number of cells secreting IFN-γ was measured after unfractionated, CD8-depleted or CD4-depleted PBMC obtained from four subjects were stimulated with the Gag peptide pool overnight in an ELISPOT plate. For subject FRRA4172, the different cell subsets were also stimulated with peptides in the p24 protein (Bg and Cg) in addition to the optimized CD8+ T-cell peptides TL9 (TPQDLNTML) and KK10 (KRWIILGLNK), restricted by his HLA-B42 and B27 HLA class I proteins, respectively.
Similar articles
- Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.
Pettersen FO, Taskén K, Kvale D. Pettersen FO, et al. Clin Exp Immunol. 2010 Aug;161(2):315-23. doi: 10.1111/j.1365-2249.2010.04179.x. Epub 2010 May 10. Clin Exp Immunol. 2010. PMID: 20491784 Free PMC article. - Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.
Zheng NN, McElrath MJ, Sow PS, Hawes SE, Diallo-Agne H, Stern JE, Li F, Mesher AL, Robinson AD, Gottlieb GS, Huang Y, Kiviat NB. Zheng NN, et al. J Virol. 2007 Sep;81(17):9061-71. doi: 10.1128/JVI.00117-07. Epub 2007 Jun 20. J Virol. 2007. PMID: 17582003 Free PMC article. - Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection.
Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel AG, Boczanowski M, Lechner A, Kim AY, Suscovich T, Brown NV, Addo MM, Walker BD. Draenert R, et al. J Virol. 2004 Jan;78(2):630-41. doi: 10.1128/jvi.78.2.630-641.2004. J Virol. 2004. PMID: 14694094 Free PMC article. - Correlation between gag-specific CD8 T-cell responses, viral load, and CD4 count in HIV-1 infection is dependent on disease status.
Jiao Y, Xie J, Li T, Han Y, Qiu Z, Zuo L, Wang A. Jiao Y, et al. J Acquir Immune Defic Syndr. 2006 Jul;42(3):263-8. doi: 10.1097/01.qai.0000221692.00091.a2. J Acquir Immune Defic Syndr. 2006. PMID: 16763520 - T cell immunity in acute HIV-1 infection.
Streeck H, Nixon DF. Streeck H, et al. J Infect Dis. 2010 Oct 15;202 Suppl 2(Suppl 2):S302-8. doi: 10.1086/655652. J Infect Dis. 2010. PMID: 20846037 Free PMC article. Review.
Cited by
- Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119.
Kalams SA, Felber BK, Mullins JI, Scott HM, Allen MA, De Rosa SC, Heptinstall J, Tomaras GD, Hu J, DeCamp AC, Rosati M, Bear J, Pensiero MN, Eldridge J, Egan MA, Hannaman D, McElrath MJ, Pavlakis GN; HIV Vaccine Trials Network 119(HVTN 119) Study Team. Kalams SA, et al. JCI Insight. 2024 Aug 1;9(18):e180819. doi: 10.1172/jci.insight.180819. JCI Insight. 2024. PMID: 39088271 Free PMC article. Clinical Trial. - Insights to HIV-1 coreceptor usage by estimating HLA adaptation with Bayesian generalized linear mixed models.
Hake A, Germann A, de Beer C, Thielen A, Däumer M, Preiser W, von Briesen H, Pfeifer N. Hake A, et al. PLoS Comput Biol. 2023 Dec 21;19(12):e1010355. doi: 10.1371/journal.pcbi.1010355. eCollection 2023 Dec. PLoS Comput Biol. 2023. PMID: 38127856 Free PMC article. - Antigen-specific and cross-reactive T cells in protection and disease.
Jiang N, Malone M, Chizari S. Jiang N, et al. Immunol Rev. 2023 Jul;316(1):120-135. doi: 10.1111/imr.13217. Epub 2023 May 20. Immunol Rev. 2023. PMID: 37209375 Free PMC article. Review. - Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller.
El Kenz B, Schmidt KG, Ogungbemi-Alt VK, Bergmann S, Steininger P, Korn K, Spriewald B, Harrer EG, Nganou-Makamdop K, Harrer T. El Kenz B, et al. Viruses. 2023 Feb 18;15(2):567. doi: 10.3390/v15020567. Viruses. 2023. PMID: 36851781 Free PMC article. - Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity.
Rosás-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW, Ramos V, Ward A, Kinloch NN, Copertino DC, Escribà T, Llano A, Brumme ZL, Brad Jones R, Mothe B, Brander C, Fox J, Nussenzweig MC, Fidler S, Caskey M, Tolstrup M, Søgaard OS. Rosás-Umbert M, et al. Nat Commun. 2022 Oct 29;13(1):6473. doi: 10.1038/s41467-022-34171-2. Nat Commun. 2022. PMID: 36309514 Free PMC article.
References
- Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69-74. - PubMed
- Anastos, K., L. A. Kalish, N. Hessol, B. Weiser, S. Melnick, D. Burns, R. Delapenha, J. DeHovitz, M. Cohen, W. Meyer, J. Bremer, and A. Kovacs. 1999. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. AIDS 13:1717-1726. - PubMed
- Barouch, D. H., S. Santra, M. J. Kuroda, J. E. Schmitz, R. Plishka, A. Buckler-White, A. E. Gaitan, R. Zin, J. H. Nam, L. S. Wyatt, M. A. Lifton, C. E. Nickerson, B. Moss, D. C. Montefiori, V. M. Hirsch, and N. L. Letvin. 2001. Reduction of simian-human immunodeficiency virus 89.6p viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75:5151-5158. - PMC - PubMed
- Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A. Lifton, C. E. Nickerson, W. L. Trigona, K. Punt, D. C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M. E. Davies, M. Chastain, T. B. Strom, R. S. Gelman, D. C. Montefiori, and M. G. Lewis. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486-492. - PubMed
- Betts, M. R., D. R. Ambrozak, D. C. Douek, S. Bonhoeffer, J. M. Benchley, J. P. Casazza, R. A. Koup, and L. J. Picker. 2001. Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75:11983-11991. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials